ORKA — Oruka Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 907654 ·
Last close
$96.32
Market Cap
$6.53B
52W High
$115.52
52W Low
$25.23
ADV30
977,146
Next earnings
2026-11-11
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -62,136,000 -49,965,000 1,231,026,000 191,519,000 33,875,000
Jun 2026 0 — -50,107,000 -41,206,000 1,139,394,000 268,470,000 27,776,000
Mar 2026 0 — -36,434,000 -31,820,000 504,480,000 49,520,000 20,691,000
Dec 2025 0 — -34,431,000 -29,583,000 488,617,000 46,935,000 19,618,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-123,643,000
Investing CF
$-606,805,000
Financing CF
$830,714,000
CapEx
$-318,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.21
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-312,148,000
Inventory
—
Receivables
—
ST Investments
$728,758,000
EBIT TTM
$-178,260,000
Pretax Income TTM
$-152,574,000
Interest Exp TTM
$0
Analysts
12

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -122,051,000 -105,433,000 488,617,000 19,618,000 468,999,000 -88,210,000
Dec 2024 — — — 396,019,000 16,729,000 379,290,000 —

TTM Snapshot

Revenues TTM
$22,184,000
NetIncome TTM
$-132,886,000
OpCashFlow TTM
—
Assets (Latest)
$1,139,394,000
Forward EPS
$-2.88

Max Pain — expiry 2027-02-19

max pain strike: $75.00 · spot: $95.74 · call oi: 47 · put oi: 3,003

Peers — same industry

TickerNameMarket CapLastDaily %
BLTE BELITE BIO, INC $6.35B $157.72 —
ARWR ARROWHEAD PHARMACEUTICALS, INC. $6.08B $42.99 —
MIRM Mirum Pharmaceuticals, Inc. $6.00B $91.95 —
AXSM Axsome Therapeutics, Inc. $7.15B $135.95 —
ABVX Abivax S.A. $7.16B $82.10 —

News headlines (Yahoo Finance, 1h cache)

Phase 2 Psoriasis Results Could Be A Big Moment For Oruka Therapeutics Stock (ORKA)
2026-11-11 01:17 · Yahoo
Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-09 21:04 · Yahoo
Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study
2026-10-27 03:02 · Yahoo
Oruka Therapeutics Soars 12% as Psoriasis Drug Clears Skin in 61% of High-Dose Patients: “A Paradigm Shift”
2026-10-26 17:45 · Yahoo
Oruka’s Psoriasis Treatment Could Generate $7B In Peak Sales, Says Guggenheim – ORKA Stock Heads For Best Day In Over 4 Months
2026-10-26 16:07 · Yahoo
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
2026-10-26 11:00 · Yahoo
Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines — The Week’s Biotech Watchlist
2026-10-26 02:28 · Yahoo
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
2026-10-25 16:00 · Yahoo
Oruka Therapeutics (ORKA) Stock May Be Trading On A Rich Premium To Book Value
2026-10-20 06:10 · Yahoo
Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says
2026-09-24 17:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.